Top

Published in:

01-10-2013 | Review Article

ANCA-associated vasculitis: report from Korea

Authors: Hye Won Kim, Yeong Wook Song

Published in: Clinical and Experimental Nephrology | Issue 5/2013

Abstract

We investigated the clinical features of Korean patients with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) by reviewing the literature. The characteristics of AAV in Korean patients were as follows: (1) granulomatous and limited disease is prevalent in granulomatosis with polyangiitis (Wegener’s) (GPA), (2) ANCA positivity is lower in GPA (56.6–68.9 %) and eosinophilic granulomatosis with polyangiitis (EGPA) (5.9–8.3 %), whereas it is higher in microscopic polyangiitis (MPA) (69–94 %), (3) C-ANCA/proteinase 3 (PR3)-ANCA positivity is 71.5–100 % in GPA and P-ANCA/myeloperoxidase (MPO)-ANCA positivity reached 94–100 % in patients with MPA, (4) renal involvement or progression to end-stage renal disease was lower in Korean patients with GPA and EGPA than in Caucasians with GPA and EGPA (according to data provided in reports). The data provided here may need to be confirmed in large-scale studies.

Available only for authorised users

Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DRW, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214–23.PubMedCrossRef

Kim HW, Kim JW, Im CH, Shin KC, Lee EY, Lee EB, et al. The clinicopathologic characteristics of granulomatosis with polyangiitis (Wegener’s): a retrospective study of 45 patients in Korea. Mod Rheumatol. 2012.

Park YB, Kim JY, Linton JA, Jung HJ, Lee SK, Shin DH. Clinicopathologic study of Wegener’s granulomatosis with special emphasis on early lesions in 10 Korean patients. Yonsei Med J. 2001;42:46–54.PubMed

Park KT, Kong IG, Han DH, Kim DW, Kim SH, Rhee CS, et al. Clinical experiences of diagnosis and treatment for Wegener’s granulomatosis. Korean J Otorhinolaryngol Head Neck Surg. 2008;51:1109–18.

Holle JU, Laudien M, Gross WL. Clinical manifestations and treatment of Wegener’s granulomatosis. Rheum Dis Clin North Am. 2010;36:507–26.PubMedCrossRef

Oh JS, Lee CK, Kim YG, Nah SS, Moon HB, Yoo B. Clinical features and outcomes of microscopic polyangiitis in Korea. J Korean Med Sci. 2009;24:269–74.PubMedCrossRef

Ahn JK, Hwang JW, Lee J, Jeon CH, Cha HS, Koh EM. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2012;32:2979–86.PubMedCrossRef

Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K, et al. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol. 2006;1:1016–22.PubMedCrossRef

Lamprecht P, Holle J, Gross WL. Update on clinical, pathophysiological and therapeutic aspects in ANCA associated vasculitides. Curr Drug Discov Technol. 2009;6:241–51.PubMedCrossRef

10.

Mahr AD, Neogi T, Lavalley MP, Davis JC, Hoffman GS, Mccune WJ, et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener’s granulomatosis. Arthritis Care Res. 2008;59:884–91.CrossRef

11.

Oh MJ, Lee JY, Kwon NH, Choi DC. Churg–Strauss syndrome: the clinical features and long-term follow-up of 17 patients. J Korean Med Sci. 2006;21:265–71.PubMedCrossRef

12.

Kim YK, Lee KS, Chung MP, Han J, Chong S, Chung MJ, et al. Pulmonary involvement in Churg–Strauss syndrome: an analysis of CT, clinical, and pathologic findings. Eur Radiol. 2007;17:3157–65.PubMedCrossRef

13.

Choi YH, Im JG, Han BK, Kim JH, Lee KY, Myoung NH. Thoracic manifestation of Churg–Strauss syndrome. Chest. 2000;117:117–24.PubMedCrossRef

14.

Kang DW, Jeong IK, Kim HJ, Lee KW. Neurologic manifestations of Churg–Strauss syndrome. J Korean Neurol Assoc. 1999;17:836–40.

15.

Seok JI, Bae JS, Joo EY, Min TH, Choi DC, Kim BJ. Clinical and electrophysiologic features of peripheral neuropathy in Churg–Strauss syndrome. J Korean Neurol Assoc. 2004;22:127–33.

16.

Keogh KA, Specks U. Churg–Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284–90.PubMedCrossRef

17.

Kang HJ, Park SH, Park JY, Shin YB, Kim CD, Tak WT, et al. Clinical characteristics of p-ANCA (anti-neutrophil cytoplasmic antibody)-related nephritis: a single center experience. Korean J Med. 2008;74:523–30.

18.

Han S, Kwon Y, Jo S, Shin J, Cha D, Cho W, et al. Patients’ and renal survival in ANCA-associated vasculitis and glomerulonephritis. Korean J Nephrol. 1999;18:409–15.

19.

Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33:1101–7.PubMedCrossRef

20.

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222–7.PubMedCrossRef

21.

Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef

22.

Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. American College of Rheumatology 1990 criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094–100.PubMedCrossRef

23.

Sehgal M, Swanson JW, DeRemee RA, Colby TV. Neurologic manifestations of Churg–Strauss syndrome. Mayo Clin Proc. 1995;70:337–41.PubMedCrossRef

24.

Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg–Strauss syndrome. Medicine (Baltimore). 1984;63:65–81.

Title: ANCA-associated vasculitis: report from Korea
Authors: Hye Won Kim
Yeong Wook Song
Publication date: 01-10-2013
Publisher: Springer Japan
Published in: Clinical and Experimental Nephrology / Issue 5/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-012-0754-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Complement in antineutrophil cytoplasmic antibody-associated vasculitis

Possible implication of disordered neutrophil extracellular traps in the pathogenesis of MPO-ANCA-associated vasculitis

Remarks on the Asia Pacific Meeting of Vasculitis and ANCA Workshop 2012

RETRACTED ARTICLE: Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease

Proposal of anti-moesin as a novel biomarker for ANCA-associated vasculitis

Antineutrophil cytoplasmic autoantibody-associated vasculitis in Chinese patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials